Background Epigenomic damage induced by Helicobacter pylori infection is accumulated in gastric mucosae before the development of malignancy. In individuals without current H. pylori infection, DNA methylation levels of specific CpG islands (CGIs) are associated with gastric cancer risk. Because risk estimation in individuals with past infection is clinically important, we here aimed to identify the risk markers that reflect epigenomic damage induced by H. pylori infection, and that are informative in these individuals. Methods Gastric mucosae were obtained from 55 gastric cancer patients (GC-Pt) (21 with current infection and 34 with past infection) and 55 healthy volunteers (HV) (7 never-infected, 21 with current infection, and 27 with past infection). Hypermethylated CGIs were searched for by methylated DNA immunoprecipitation-CGI microarray, and methylation levels were analyzed by quantitative methylation-specific polymerase chain reaction (PCR).
Introduction
Early detection of cancer is critically important to reduce its morbidity and mortality, and early detection can be achieved by identifying individuals at high risk of developing cancers. In the risk estimation of gastric cancers, a history of Helicobacter pylori infection, which increases gastric cancer risk 2.2-to 21-fold [1] [2] [3] [4] , plays the major role, but the vast majority of individuals with a history of H. pylori infection do not develop gastric cancers. Also, gene polymorphisms associated with gastric cancers have been identified, and they have been shown to confer odds ratios (ORs) mostly between 1.0 and 2.0 [5, 6] . To obtain clinically useful risk markers, we have to develop markers that are informative even in individuals with a history of H. pylori infection and that confer higher ORs.
Recently, we showed that H. pylori infection induces epigenomic damage, especially aberrant DNA methylation, in gastric mucosae [7] . DNA methylation levels of specific CpG islands (CGIs) were very high in the gastric mucosae of individuals with active H. pylori infection irrespective of gastric cancer risk, and decreased to certain levels after H. pylori was eradicated [8] . Importantly, these methylation levels in individuals without active H. pylori infection were correlated with gastric cancer risk [7, 9] . It is considered that aberrant DNA methylation is induced both in gastric stem cells and in non-stem cells, that methylation induced in stem cells will remain even after H. pylori eradication, and that methylation levels in individuals without current H. pylori infection reflect gastric cancer risk (degree of the epigenetic field defect) [10] .
The correlation between methylation levels and gastric cancer risk has been analyzed in individuals without current H. pylori infection [7, 9] . Based on the data in our previous study [7] , currently available methylation risk markers, FLNc and THBD, have ORs of 4.2-7.0 to detect gastric cancer patients (GC-Pt) among such individuals. However, individuals without current H. pylori infection indeed consist of never-infected individuals and those with past infection, and risk estimation is important in individuals with past infection.
In this study, we aimed to identify gastric cancer risk markers that reflect epigenomic damage induced by H. pylori infection, and that are informative in individuals with past infection.
Materials and methods

Tissue samples and determination of H. pylori infection status
Fifty-five healthy volunteers (HV) with endoscopic findings of no malignancy were recruited, with written informed consents, on the occasion of a gastric cancer screening program, with the approval of the institutional review board. Fifty-five GC-Pt who had undergone curative endoscopic submucosal dissection (ESD) of a welldifferentiated adenocarcinoma in the non-cardia according to the Japanese classification of gastric carcinoma [11] were also recruited, with written informed consents, with the approval of the Institutional Review Board. Gastric mucosae were collected by endoscopic biopsy of the antrum. The biopsy specimens were frozen in liquid nitrogen immediately after biopsy, and stored at -80°C until DNA extraction. High molecular weight DNA was extracted by the phenol/chloroform method. Current H. pylori infection was analyzed by a serum anti-H. pylori IgG antibody test (SRL, Tokyo, Japan) in HV and by urea breath test (Otsuka Pharmaceutical, Tokushima, Japan) in GC-Pt. Also, the presence of current or past H. pylori infection was detected by the endoscopic presence of atrophic gastritis in the antrum, because atrophic change induced by H. pylori infection arises in the antrum in 83% of individuals with H. pylori infection [12] and remains in all individuals who have had H. pylori eradication therapy [13] . ''Never-infected individuals'' were defined as those who were negative for H. pylori analysis and did not have atrophic gastritis in the antrum. ''Individuals with current infection'' were defined as those who were positive for H. pylori analysis. ''Individuals with past infection'' were defined as those who were negative for H. pylori analysis and had atrophic gastritis in the antrum.
Methylated DNA immunoprecipitation-CGI microarray analysis
Methylated DNA immunoprecipitation (MeDIP)-CGI microarray analysis was performed as previously described [14, 15] . Briefly, 5 lg of genomic DNA was immunoprecipitated with an anti-5-methylcytidine antibody (Diagnode, Liége, Belgium), and the precipitated DNA and the input DNA were labeled with cyanin (Cy) 5 and Cy3, respectively. A human CGI oligonucleotide microarray (Agilent Technologies, Santa Clara, CA, USA) was hybridized with the labeled probes and scanned with an Agilent G2565BA microarray scanner (Agilent Technologies). Scanned data were processed with Feature Extraction Software Version 9.1 (Agilent Technology) and Agilent G4477AA ChIP Analytics 1.3 software. The signal of a probe was converted into a ''Me value'', which represented the methylation level as a value from 0 (unmethylated) to 1 (methylated). Differentially methylated regions were detected by comparison between the Me values of two samples, and data were visualized in the UCSC Genome Browser (http://genome. ucsc.edu/) on NCBI36/hg18 assembly (National Center for Biotechnology Information, Bethesda, MD, USA).
Sodium bisulfite modification and quantitative methylation-specific polymerase chain reaction Fully methylated DNA and fully unmethylated DNA were prepared by methylating genomic DNA with SssI methylase (New England Biolabs, Beverly, MA, USA) and by amplifying genomic DNA with the GenomiPhi amplification system (GE Healthcare, Buckinghamshire, UK), respectively. Bisulfite modification was performed using 1 lg of BamHI-digested genomic DNA, and the modified DNA was suspended in 40 ll of Tris-ethylenediamine tetraacetic acid (EDTA) buffer [16] . An aliquot of 2 ll of sodium bisulfite-treated DNA was used in one reaction of quantitative methylation-specific polymerase chain reaction (PCR; qMSP).
qMSP was performed using primer sets specific to methylated and unmethylated sequences (Supplementary Table 1 ), SYBR Ò Green I (BioWhittaker Molecular Applications, Rockland, ME, USA), and an iCycler Thermal Cycler (Bio-Rad Laboratories, Hercules, CA, USA). The number of molecules in a sample was determined by comparing its amplification with those of standard DNA that contained known numbers of molecules (10 1 -10 9 molecules). Standard DNA was prepared by purifying the PCR products using the Wizard SV Gel and PCR Clean-Up System (Promega, Fitchburg, WI, USA). The methylation level was calculated as the fraction of methylated (M) molecules in the total number of DNA molecules (number of M molecules ? number of unmethylated molecules). The percentage of methylated reference (PMR) was calculated as the fraction of the methylated reference {(number of M molecules in a sample)/(number of Alu repeat sequences in a sample)}/{(number of M molecules in SssI-treated DNA)/(number of Alu repeat sequences in SssI-treated DNA)} [17] .
Statistical analysis
Differences in mean methylation levels or PMR were analyzed by the Student's t-test. The receiver-operating characteristic (ROC) curve was drawn, and the area under the curve (AUC) and OR were analyzed by binomial distribution and binomial logistic regression analysis, respectively. All the analysis was performed using PASW statistics (SPSS, Chicago, IL, USA), and the results were considered significant when P values of less than 0.05 were obtained by two-sided tests.
Results
Isolation of hypermethylated CGIs in GC-Pt compared with HV in individuals with past H. pylori infection
A pool of three samples from HV with past infection and another pool of three samples from GC-Pt with past infection were analyzed by MeDIP-CGI microarray analysis. CGIs that were hypermethylated in the latter group compared with the former group were selected as follows:
(1) Me value in the latter pool was higher than that in the former pool by 0.2 or more, (2) Me value in the former pool was lower than 0.4, and (3) criteria (1) and (2) were satisfied in three consecutive probes. A total of 15 CGIs were isolated by these criteria (Table 1) , and representative data around CGI #5 are shown in Fig. 1 . From the 15 CGIs, those differentially methylated in a screening set, which consisted of 10 HV with past infection and 10 GC-Pt with past infection, were searched for by evaluating PMRs by qMSP (Supplementary Table 2 ). Seven CGIs (#1 to #7; Table 1 ), distributed on various chromosomes, were methylated at significantly higher CGI CpG island, MeDIP methylated DNA immunoprecipitation levels in GC-Pt than in HV (P \ 0.05). Relative positions against a gene also varied-two CGIs being located in exon 1, two in intron 1, two 300 bp downstream of the annotated end, and one overlapping with pre-microRNA 663.
Validation of the usefulness of the seven markers
The usefulness of the seven CGIs was validated by qMSP analysis of an independent set of samples (Fig. 2) . Table 3 ). For comparison, two currently available markers (FLNc and THBD) were also analyzed. In the individuals with past infection (G3 and G5), the seven CGIs had levels that were 2.8-, 1.5-, 3.8-, 2.3-, 2.5-, 1.8-, and 3.8-fold, respectively, higher in G5 than in G3 (P \ 0.01). FLNc tended to have a higher level in G5 than in G3 (P = 0.087), but THBD did not show any significant difference (P = 0.341). These data showed that the methylation levels of all the seven CGIs had the power of cancer risk estimation even in individuals with past infection.
The validation set consisted of seven never-infected HV (Group [G] 1), 21 HV with current infection (G2), 14 HV with past infection (G3), 21 GC-Pt with current infection (G4), and 21 GC-Pt with past infection (G5) (Supplementary
In the HV, methylation levels in G2 were much higher than those in G1 (P \ 0.05), but those in G3 were lower than those in G2. This observation supported the model that active infection by H. pylori induces methylation potently in non-stem cells, in addition to stem cells, and that methylation levels will eventually decrease after H. pylori infection has been eradicated. Also, methylation levels in G3 were significantly higher (four of the seven CGIs, P \ 0.05) or tended to be higher than those in G1. This observation again supported the model that methylation induced in stem cells will remain even after H. pylori infection is eradicated.
Power of the seven CGIs as gastric cancer risk markers
AUCs to detect individuals in G5 were calculated using individuals in G3 and G5 (Table 2 ; Fig. 3) . AUCs for the seven CGIs ranged between 0.78 and 0.84 and were significantly larger than 0.5 (P \ 0.01). In contrast, the AUCs for the two currently available markers were 0.69 (95% CI 0.51-0.87) and 0.65 (95% CI 0.45-0.84), respectively, and were not significantly different from 0.5. Using optimal cut-off values obtained by the ROCs, ORs for the seven CGIs were calculated to be 12.7-36.0 (Table 2) . ORs for Methylation levels of the seven CGIs in Group 5 (G5) were significantly higher than those in G3 (P \ 0.01), but there were no significant differences for the two currently available markers. *P \ 0.05, **P \ 0.01, ***P \ 0.001 the two currently available markers, FLNc and THBD, were 5.7 (95% CI 1.2-25.9) and 5.0 (95% CI 1.1-21.8), respectively. These results clearly showed that the methylation levels of the seven CGIs had greater power than the two currently available markers to estimate gastric cancer risk in individuals with past infection.
Discussion
In the present study, by carrying out genome-wide methylation analysis of gastric cancer patients (GC-Pt) and healthy volunteers (HV), both with past infection, we screened seven gastric cancer risk markers that are highly informative in individuals with past infection. Their usefulness was validated in 35 individuals (21 GC-Pt and 14 age-matched HV). To our knowledge, this is the first study that has evaluated epigenetic gastric cancer risk markers in individuals with past infection, and these markers are expected to be especially useful. This is because the number of individuals with past infection is increasing as more and more people receive H. pylori eradication therapy [18] , but the usefulness of the current methods for gastric cancer risk estimation, i.e., a combination of the detection of H. pylori infection and the serum pepsinogen test, in this population has not been established [18] [19] [20] .
None of the seven CGIs were located in promoter regions. We analyzed the association between the methylation levels of the seven CGIs and the expression levels of genes close to them, but no association was observed for any of the seven CGIs (data not shown). This was in line with the current knowledge that DNA methylation of only promoter CGIs consistently causes gene silencing, but that methylation of gene bodies may or may not be associated with increased expression [14, 21, 22] . The lack of association between methylation and gene expression supported the hypothesis that the methylation of these seven CGIs reflects the degree of overall epigenomic damage in gastric stem cells, and that the degree of epigenomic damage, and not the change of expression of individual genes, is associated with gastric cancer risk.
Epigenomic damage induced by H. pylori infection is one of the major causes of gastric cancer [23] [24] [25] [26] , but it is not known whether the epigenomic damage is independent of other risk factors. For example, salt intake is a risk factor for gastric cancer [27, 28] , and although it does not induce methylation in gastric mucosae by itself in a Mongolian gerbil model [29, 30] , it shows synergistic effects with H. pylori on cancer development [31] . It is not known yet whether epigenomic damage in the gastric mucosa provides independent information from past salt exposure or whether the exposure is already reflected in methylation levels. Multivariate analysis in a large cohort with a reliable record of history of salt intake will clarify this issue, and might provide a risk marker that complements the epigenetic gastric cancer risk markers.
In conclusion, we identified seven CGIs whose methylation levels are increased after H. pylori infection, and are associated with gastric cancer risk even in individuals with past infection. These seven CGIs are promising candidate markers to estimate gastric cancer risk.
